ABVC Biopharma (NASDAQ: ABVC) — Company Overview, News & Financial Data
ABVC Biopharma develops therapeutic and diagnostic products focused on oncology, CNS disorders, and ophthalmology.
ABVC Biopharma
ABVC Biopharma (NASDAQ:ABVC) is a biopharmaceutical company focused on developing and commercializing a diverse range of therapeutic and diagnostic products. It aims to address unmet medical needs in areas such as oncology, central nervous system disorders, and ophthalmology through its innovative research and development strategies. The company's projects range from early-stage discovery to advanced clinical trials, with a commitment to bringing novel treatments and solutions to patients worldwide. ABVC Biopharma pursues partnerships and collaborations to accelerate its product development pipeline and expand its market reach, with the goal of improving patient outcomes and delivering shareholder value.
Snapshot
Operations
Products and/or services of ABVC Biopharma
- Development of the AD101, aimed at treating Alzheimer's Disease, focusing on cognitive enhancement.
- Biological drug ABV-1501 for treating Major Depressive Disorder, enhancing mood without traditional antidepressant side effects.
- ABV-1703 targets Pancreatic Cancer, offering potential new therapeutic approach.
- Innovative drug ABV-1504 for Asthma and Chronic Obstructive Pulmonary Disease (COPD), aimed at improving respiratory function.
- ABV-1601, designed to address Chronic Kidney Disease, focusing on renal function improvement.
- Technology platform for Personalized Cancer Medicine, facilitating individualized treatment plans.
ABVC Biopharma executive team
- Eugene JiangChairman & Chief Business Officer
- Uttam Yashwant PatilCEO & Interim CFO
- Tsung-Shann JiangChief Scientific Officer, Chief Strategy Officer & Director
Key financials
Reported results for ABVC Biopharma, in USD.
- Market cap
- 26.3M
- Revenue (TTM)
- 797.9K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 796K | -7.2M | -7.9M | |
| 509.6K | -4.7M | -4.9M | |
| 152.4K | -6.8M | -7.8M | |
| 969.8K | -15.1M | -16.4M |